An elegant mathematical model supported by experiments in Escherichia coli demonstrates how clustering enzymes can efficiently channel intermediates from one enzyme to the next, facilitating rational engineering of metabolism. We present a quantitative model to demonstrate that coclustering multiple enzymes into compact agglomerates accelerates the processing of intermediates, yielding the same efficiency benefits as direct channeling, a well-known mechanism in which enzymes are funneled between enzyme active sites through a physical tunnel. The model predicts the separation and size of coclusters that maximize metabolic efficiency, and this prediction is in agreement with previously reported spacings between coclusters in mammalian cells. For direct validation, we study a metabolic branch point in Escherichia coli and experimentally confirm the model prediction that enzyme agglomerates can accelerate the processing of a shared intermediate by one branch, and thus regulate steady-state flux division. Our studies establish a quantitative framework to understand coclustering-mediated metabolic channeling and its application to both efficiency improvement and metabolic regulation.
The COVID-19 pandemic has created massive demand for widespread, distributed tools for detecting SARS-CoV-2 genetic material. The hurdles to scalable testing include reagent and instrument accessibility, availability of highly trained personnel, and large upfront investment.
Significance: The roseobacter constitute nearly 25% of marine bacteria in coastal areas. They have been shown to produce a potent antibiotic, tropodithietic acid (TDA), which confers far-reaching aquacultural and ecological benefits. We have examined the mode of action of TDA using a number of methods including bacterial cytological profiling. Surprisingly, TDA clusters with molecules that are structurally unrelated and highly cytotoxic. Subsequent screens demonstrate that, aside from its antibacterial activity, TDA is also a potent, broad-range, and potentially useful anticancer agent. Our studies highlight the power of profiling methods in repurposing bioactive compounds, reveal the mode of action of the unusual troponoid TDA, and uncover a previously unknown link between two metabolic cycles, which together provide TDA resistance to the producing roseobacter.